NimbleGen Will Help Upstream Validate Biomarkers
 
NimbleGen will help Upstream Biosciences validate biomarkers, Upstream said this week.
 
Under the agreement, NimbleGen will provide lab services including its whole-genome chromatin immunoprecipitation arrays to validate in silico binding-site predictions, Upstream said.
 
Upstream said it has filed five patents that would cover the use of genetic variations in certain regions that mark "various" cancers.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.